- Incyte drops early-stage JAK2 inhibitor to prioritize next-generation pipelineIncyte announced it is terminating development of its early-stage oral JAK2 inhibitor, INCB160058, after a Phase 1 study in myeloproliferative neoplasms. The company said the decision reflects the…
- Former VA Secretary argues the Veterans Health Administration can boost US biotech competitiveness against ChinaThe piece, authored by former Veterans Affairs Secretary David Shulkin, positions the VA as a critical component of America’s biotechnology ecosystem alongside HHS and the Department of Defense. H…